Drug Profile
Naquotinib - Astellas Pharma
Alternative Names: ASP8273Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 30 Jan 2018 Chemical structure information added
- 02 Jun 2017 Efficacy and adverse events data from a phase-II trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
- 10 May 2017 Discontinued - Phase-I for Solid tumours (Metastatic disease, Late-stage disease, Unresectable/Inoperable) in USA (PO)